Update on Treating Painful Diabetic Peripheral Neuropathy: A Review of Current US Guidelines with a Focus on the Most Recently Approved Management Options

References

• Ang L, Mizokami-Stout K, Eid SA, et al. The conundrum of diabetic neuropathies-Past, present, and future. J Diabetes Complications. 2022;36(11):108334. doi:10.1016/j.jdiacomp.2022.108334
   PubMed Web of Science ®Google Scholar
• Jensen TS, Karlsson P, Gylfadottir SS, et al. Painful and non-painful diabetic neuropathy, diagnostic challenges and implications for future management. Brain. 2021;144(6):1632–1645. doi:10.1093/brain/awab079
   PubMedGoogle Scholar
• Diabetes. Centers for Disease Control and Prevention; 2021. Available from: https://www.cdc.gov/diabetes/basics/diabetes.html. Accessed September 29, 2023.
   Google Scholar
• Hicks CW, Selvin E. Epidemiology of peripheral neuropathy and lower extremity disease in diabetes. Curr Diab Rep. 2019;19(10):86. doi:10.1007/s11892-019-1212-8
   PubMed Web of Science ®Google Scholar
• Anastasi JK, Capili B. Detecting peripheral neuropathy in patients with diabetes, prediabetes and other high-risk conditions: an advanced practice nurse’s perspective. J Med Clin Nurs. 2022;3(2):143. doi:10.47363/jmcn/2022(3)143
   PubMedGoogle Scholar
• Iqbal Z, Azmi S, Yadav R, et al. Diabetic peripheral neuropathy: epidemiology, diagnosis, and pharmacotherapy. Clin Ther. 2018;40(6):828–849. doi:10.1016/j.clinthera.2018.04.001
   PubMed Web of Science ®Google Scholar
• Sloan G, Selvarajah D, Tesfaye S. Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy. Nat Rev Endocrinol. 2021;17(7):400–420. doi:10.1038/s41574-021-00496-z
   PubMed Web of Science ®Google Scholar
• Feldman EL, Callaghan BC, Pop-Busui R, et al. Diabetic neuropathy. Nat Rev Dis Primers. 2019;5(1):41. doi:10.1038/s41572-019-0092-1
   PubMed Web of Science ®Google Scholar
• Gupta M, Knezevic NN, Abd-Elsayed A, Ray M, Patel K, Chowdhury B. Treatment of painful diabetic neuropathy-A narrative review of pharmacological and interventional approaches. Biomedicines. 2021;9(5):573. doi:10.3390/biomedicines9050573
   PubMed Web of Science ®Google Scholar
• Staudt MD, Prabhala T, Sheldon BL, et al. Current strategies for the management of painful diabetic neuropathy. J Diabetes Sci Technol. 2022;16(2):341–352. doi:10.1177/1932296820951829
   PubMedGoogle Scholar
• Naranjo C, Del Reguero L, Moratalla G, et al. Anxiety, depression and sleep disorders in patients with diabetic neuropathic pain: a systematic review. Expert Rev Neurother. 2019;19(12):1201–1209. doi:10.1080/14737175.2019.1653760
   PubMed Web of Science ®Google Scholar
• Elafros MA, Andersen H, Bennett DL, et al. Towards prevention of diabetic peripheral neuropathy: clinical presentation, pathogenesis, and new treatments. Lancet Neurol. 2022;21(10):922–936. doi:10.1016/S1474-4422(22)00188-0
   PubMed Web of Science ®Google Scholar
• Sloan G, Shillo P, Selvarajah D, et al. A new look at painful diabetic neuropathy. Diabet Res Clin Pract. 2018;144:177–191. doi:10.1016/j.diabres.2018.08.020
   PubMed Web of Science ®Google Scholar
• Javed S, Alam U, Malik RA. Treating diabetic neuropathy: present strategies and emerging solutions. Rev Diabet Stud. 2015;12(1–2):63–83. doi:10.1900/rds.2015.12.63
   PubMedGoogle Scholar
• Tesfaye S, Boulton AJ, Dyck PJ, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33(10):2285–2293. doi:10.2337/dc10-1303
   PubMed Web of Science ®Google Scholar
• St Onge EL, Miller SA. Pain associated with diabetic peripheral neuropathy: a review of available treatments. P T. 2008;33(3):166–176.
   PubMedGoogle Scholar
• Tesfaye S, Boulton AJM, Dickenson AH. Mechanisms and management of diabetic painful distal symmetrical polyneuropathy. Diabetes Care. 2013;36(9):2456–2465. doi:10.2337/dc12-1964
   PubMed Web of Science ®Google Scholar
• Price R, Smith D, Franklin G, et al. Oral and topical treatment of painful diabetic polyneuropathy: practice guideline update summary: report of the AAN Guideline Subcommittee. Neurology. 2022;98(1):31–43. doi:10.1212/wnl.0000000000013038
   PubMed Web of Science ®Google Scholar
• Pop-Busui R, Boulton AJM, Feldman EL, et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care. 2017;40(1):136–154. doi:10.2337/dc16-2042
   PubMed Web of Science ®Google Scholar
• Pop-Busui R, Ang L, Boulton AJM, et al. Diagnosis and Treatment of Painful Diabetic Peripheral Neuropathy. Arlington (VA): American Diabetes Association, Inc.; 2022.
   Google Scholar
• Blonde L, Umpierrez GE, Reddy SS, et al. American Association of Clinical Endocrinology Clinical Practice Guideline: developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. Endocr Pract. 2022;28(10):923–1049. doi:10.1016/j.eprac.2022.08.002
   PubMed Web of Science ®Google Scholar
• Ziegler D, Keller J, Maier C, Pannek J. Diabetic neuropathy. Exp Clin Endocrinol Diabetes. 2021;129:S70–S81. doi:10.1055/a-1284-6245
   PubMed Web of Science ®Google Scholar
• James CF, Tripathi S, Karampatou K, Gladston DV, Pappachan JM. Pharmacotherapy of Painful Diabetic Neuropathy: a Clinical Update. Sisli Etfal Hastan Tip Bul. 2022;56(1):1–20. doi:10.14744/semb.2021.54670
   PubMed Web of Science ®Google Scholar
• Rafiullah M, Siddiqui K. Pharmacological Treatment of Diabetic Peripheral Neuropathy: an Update. CNS Neurol Disord Drug Targets. 2022;21(10):884–900. doi:10.2174/1871527320666210303111939
   PubMed Web of Science ®Google Scholar
• Mick G, Baron R, Correa-Illanes G, et al. Is an easy and reliable diagnosis of localized neuropathic pain (LNP) possible in general practice? Development of a screening tool based on IASP criteria. Curr Med Res Opin. 2014;30(7):1357–1366. doi:10.1185/03007995.2014.907562
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Introduction: standards of Medical Care in Diabetes—2022. Diabetes Care. 2022;45(Supplement_1):S1–S2. doi:10.2337/dc22-Sint
   PubMedGoogle Scholar
• American Diabetes Association Professional Practice Committee. 12. Retinopathy, Neuropathy, and Foot Care: standards of Medical Care in Diabetes—2022. Diabetes Care. 2022;45(Supplement_1):S185–S194. doi:10.2337/dc22-S012
   PubMedGoogle Scholar
• Khdour MR. Treatment of diabetic peripheral neuropathy: a review. J Pharm Pharmacol. 2020;72(7):863–872. doi:10.1111/jphp.13241
   PubMed Web of Science ®Google Scholar
• Ziegler D, Tesfaye S, Spallone V, et al. Screening, diagnosis and management of diabetic sensorimotor polyneuropathy in clinical practice: international expert consensus recommendations. Diabet Res Clin Pract. 2022;186:109063. doi:10.1016/j.diabres.2021.109063
   PubMed Web of Science ®Google Scholar
• Finnerup NB, Attal N, Haroutounian S, McNicol E. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162–173. doi:10.1016/S1474-4422(14)70251-0
   PubMed Web of Science ®Google Scholar
• van Dam PS, Valk GD, Bakker K. [Diabetic peripheral neuropathy: international guidelines for prevention, diagnosis, and treatment]. Ned Tijdschr Geneeskd. 2000;144(9):418–421.
   PubMedGoogle Scholar
• Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17(9):1113–e88. doi:10.1111/j.1468-1331.2010.02999.x
   PubMed Web of Science ®Google Scholar
• Boulton AJ. Guidelines for diagnosis and outpatient management of diabetic peripheral neuropathy. European Association for the Study of Diabetes. Neurodiab Diabetes Metab. 1998;24(Suppl 3):55–65.
   PubMedGoogle Scholar
• Tan T, Barry P, Reken S, Baker M. Pharmacological management of neuropathic pain in non-specialist settings: summary of NICE guidance. BMJ. 2010;340:c1079. doi:10.1136/bmj.c1079
   PubMedGoogle Scholar
• Moulin D, Boulanger A, Clark AJ, et al. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res Manag. 2014;19(6):328–335. doi:10.1155/2014/754693
   PubMed Web of Science ®Google Scholar
• Schlereth T. Guideline “diagnosis and non interventional therapy of neuropathic pain” of the German Society of Neurology (deutsche Gesellschaft für Neurologie). Neurol Res Pract. 2020;2(1):16. doi:10.1186/s42466-020-00063-3
   PubMedGoogle Scholar
• Haslbeck M, Neundörfer B, Wilm S. German national disease management guidelines ”diabetic neuropathy”. Important implications on clinical practice. MMW Fortschr Med. 2011;153(49–50):1.
   Google Scholar
• Intellis™, Vanta™, Sequentia™ LT neurostimulation systems for pain therapy: information for prescribers. Minneapolis, MN: Medtronic, Inc.; 2021.
   Google Scholar
• Senza®, Senza II™, Senza Omnia™ (spinal cord stimulation systems): US physician implant manual. Redwood City, CA: Nevro Corp.; 2020.
   Google Scholar
• Qutenza® (Capsaicin) Topical System: US Prescribing Information. Morristown, NJ: Averitas Pharma, Inc; 2023.
   Google Scholar
• Nucynta® ER (tapentadol) extended-release tablets, for oral use C-II: US prescribing information. Stoughton, MA: Collegium Pharmaceutical, Inc.; 2021.
   Google Scholar
• Drizalma Sprinkle™ (Duloxetine Delayed-Release Capsules), for Oral Use: US Prescribing Information. Cranbury, NJ: Sun Pharmaceuticals Industries Limited; 2021.
   Google Scholar
• Cymbalta® (Duloxetine Delayed-Release Capsules), for Oral Use: US Prescribing Information. Indianapolis, IN: Eli Lilly and Company; 2021.
   Google Scholar
• Lyrica® (Pregabalin) Capsules and Solution, for Oral Use: US Prescribing Information. New York, NY: Pfizer Inc.; 2020.
   Google Scholar
• Strand NH, Burkey AR. Neuromodulation in the treatment of painful diabetic neuropathy: a review of evidence for spinal cord stimulation. J Diabetes Sci Technol. 2022;16(2):332–340. doi:10.1177/19322968211060075
   PubMedGoogle Scholar
• de Vos CC, Meier K, Zaalberg PB, et al. Spinal cord stimulation in patients with painful diabetic neuropathy: a multicentre randomized clinical trial. Pain. 2014;155(11):2426–2431. doi:10.1016/j.pain.2014.08.031
   PubMed Web of Science ®Google Scholar
• Slangen R, Schaper NC, Faber CG, et al. Spinal cord stimulation and pain relief in painful diabetic peripheral neuropathy: a prospective two-center randomized controlled trial. Diabetes Care. 2014;37(11):3016–3024. doi:10.2337/dc14-0684
   PubMed Web of Science ®Google Scholar
• Petersen EA, Stauss TG, Scowcroft JA, et al. Effect of high-frequency (10-kHz) spinal cord stimulation in patients with painful diabetic neuropathy: a randomized clinical trial. JAMA Neurol. 2021;78(6):687–698. doi:10.1001/jamaneurol.2021.0538
   PubMed Web of Science ®Google Scholar
• Clinical evidence on SCS for painful DPN. Minneapolis, MN: Medtronic; 2022. Available from https://www.medtronic.com/content/dam/medtronic-com/us-en/hcp/therapies-conditions/neurological/spinal-cord-stimulation/scs-pdn-clinical-evidence-compendium.pdf. Accessed September 12, 2023.
   Google Scholar
• Duarte RV, Nevitt S, Copley S, et al. Systematic review and network meta-analysis of neurostimulation for painful diabetic neuropathy. Diabetes Care. 2022;45(10):2466–2475. doi:10.2337/dc22-0932
   PubMed Web of Science ®Google Scholar
• Duarte RV, Nevitt S, Maden M, et al. Spinal cord stimulation for the management of painful diabetic neuropathy: a systematic review and meta-analysis of individual patient and aggregate data. Pain. 2021;162(11):2635–2643. doi:10.1097/j.pain.0000000000002262
   PubMed Web of Science ®Google Scholar
• Pluijms WA, Slangen R, Bakkers M, et al. Pain relief and quality-of-life improvement after spinal cord stimulation in painful diabetic polyneuropathy: a pilot study. Br J Anaesth. 2012;109(4):623–629. doi:10.1093/bja/aes251
   PubMed Web of Science ®Google Scholar
• van Beek M, Geurts JW, Slangen R, et al. Severity of neuropathy is associated with long-term spinal cord stimulation outcome in painful diabetic peripheral neuropathy: five-year follow-up of a prospective two-center clinical trial. Diabetes Care. 2018;41(1):32–38. doi:10.2337/dc17-0983
   PubMed Web of Science ®Google Scholar
• Zuidema X, van Daal E, van Geel I, et al. Long-term evaluation of spinal cord stimulation in patients with painful diabetic polyneuropathy: an eight-to-ten-year prospective cohort study. Neuromodulation. 2023;26(5):1074–1080. doi:10.1016/j.neurom.2022.12.003
   PubMed Web of Science ®Google Scholar
• Petersen EA, Stauss TG, Scowcroft JA, et al. Durability of high-frequency 10-kHz spinal cord stimulation for patients with painful diabetic neuropathy refractory to conventional treatments: 12-month results from a randomized controlled trial. Diabetes Care. 2022;45(1):e3–e6. doi:10.2337/dc21-1813
   PubMed Web of Science ®Google Scholar
• The Nobel Prize. The Nobel Prize in Physiology or Medicine 2021 was awarded jointly to David Julius and Ardem Patapoutian “for their discoveries of receptors for temperature and touch”. Available from https://www.nobelprize.org/prizes/medicine/2021/summary/. Accessed September 28, 2023.
   Google Scholar
• Anand P, Bley K. Topical capsaicin for pain management: therapeutic potential and mechanisms of action of the new high-concentration capsaicin 8% patch. Br J Anaesth. 2011;107(4):490–502. doi:10.1093/bja/aer260
   PubMed Web of Science ®Google Scholar
• Baranidharan G, Das S, Bhaskar A. A review of the high-concentration capsaicin patch and experience in its use in the management of neuropathic pain. Ther Adv Neurol Disord. 2013;6(5):287–297. doi:10.1177/1756285613496862
   PubMed Web of Science ®Google Scholar
• Wohlrab J, Neubert RH, Heskamp ML, Michael J. Cutaneous drug delivery of capsaicin after in vitro administration of the 8% capsaicin dermal patch system. Skin Pharmacol Physiol. 2015;28(2):65–74. doi:10.1159/000362740
   PubMed Web of Science ®Google Scholar
• Leppert W, Malec-Milewska M, Zajaczkowska R, Wordliseck Z. Transdermal and topical drug administration in the treatment of pain. Molecules. 2018;23(3):681. doi:10.3390/molecules23030681
   PubMed Web of Science ®Google Scholar
• Frias B, Merighi A. Capsaicin, nociception and pain. Molecules. 2016;21(6):797. doi:10.3390/molecules21060797
   PubMed Web of Science ®Google Scholar
• Noto C, Pappagallo M, Szallasi A. NGX-4010, a high-concentration capsaicin dermal patch for lasting relief of peripheral neuropathic pain. Curr Opin Invest Drugs. 2009;10(7):702–710.
   PubMedGoogle Scholar
• Premkumar LS, Sikand P. TRPV1: a target for next generation analgesics. Curr Neuropharmacol. 2008;6(2):151–163. doi:10.2174/157015908784533888
   PubMed Web of Science ®Google Scholar
• Malmberg AB, Mizisin AP, Calcutt NA, von Stein T, Robbins WR, Bley KR. Reduced heat sensitivity and epidermal nerve fiber immunostaining following single applications of a high-concentration capsaicin patch. Pain. 2004;111(3):360–367. doi:10.1016/j.pain.2004.07.017
   PubMed Web of Science ®Google Scholar
• Lo Vecchio S, Andersen HH, Arendt-Nielsen L. The time course of brief and prolonged topical 8% capsaicin-induced desensitization in healthy volunteers evaluated by quantitative sensory testing and vasomotor imaging. Exp Brain Res. 2018;236(8):2231–2244. doi:10.1007/s00221-018-5299-y
   PubMed Web of Science ®Google Scholar
• Nolano M, Simone DA, Wendelschafer-Crabb G, Johnson T, Hazen E, Kennedy WR. Topical capsaicin in humans: parallel loss of epidermal nerve fibers and pain sensation. Pain. 1999;81(1–2):135–145. doi:10.1016/s0304-3959(99)00007-x
   PubMed Web of Science ®Google Scholar
• Kennedy WR, Vanhove GF, Lu SP, Tobias J. A randomized, controlled, open-label study of the long-term effects of NGX-4010, a high-concentration capsaicin patch, on epidermal nerve fiber density and sensory function in healthy volunteers. J Pain. 2010;11(6):579–587. doi:10.1016/j.jpain.2009.09.019
   PubMed Web of Science ®Google Scholar
• Anand P, Privitera R, Donatien P, et al. Reversing painful and non-painful diabetic neuropathy with the capsaicin 8% patch: clinical evidence for pain relief and restoration of function via nerve fiber regeneration. Front Neurol. 2022;13:998904. doi:10.3389/fneur.2022.998904
   PubMed Web of Science ®Google Scholar
• Sendel M, Dunst A, Forstenpointner J, Hüllemann P, Baron R. Capsaicin treatment in neuropathic pain: axon reflex vasodilatation after 4 weeks correlates with pain reduction. Pain. 2023;164(3):534–542. doi:10.1097/j.pain.0000000000002735
   PubMed Web of Science ®Google Scholar
• Anand P, Elsafa E, Privitera R, et al. Rational treatment of chemotherapy-induced peripheral neuropathy with capsaicin 8% patch: from pain relief towards disease modification. J Pain Res. 2019;12:2039–2052. doi:10.2147/jpr.S213912
   PubMed Web of Science ®Google Scholar
• Anand P, Privitera R, Donatien P, Misra VP, Woods DR. Capsaicin 8% patch treatment in non-freezing cold injury: evidence for pain relief and nerve regeneration. Front Neurol. 2021;12:722875. doi:10.3389/fneur.2021.722875
   PubMed Web of Science ®Google Scholar
• Babbar S, Marier JF, Mouksassi MS, et al. Pharmacokinetic analysis of capsaicin after topical administration of a high-concentration capsaicin patch to patients with peripheral neuropathic pain. Ther Drug Monit. 2009;31(4):502–510. doi:10.1097/FTD.0b013e3181a8b200
   PubMed Web of Science ®Google Scholar
• Simpson DM, Robinson-Papp J, Van J, et al. Capsaicin 8% patch in painful diabetic peripheral neuropathy: a randomized, double-blind, placebo-controlled study. J Pain. 2017;18(1):42–53. doi:10.1016/j.jpain.2016.09.008
   PubMed Web of Science ®Google Scholar
• Vinik AI, Perrot S, Vinik EJ, et al. Capsaicin 8% patch repeat treatment plus standard of care (SOC) versus SOC alone in painful diabetic peripheral neuropathy: a randomised, 52-week, open-label, safety study. BMC Neurol. 2016;16(1):251. doi:10.1186/s12883-016-0752-7
   PubMed Web of Science ®Google Scholar
• Vinik AI, Perrot S, Vinik EJ, et al. Repeat treatment with capsaicin 8% patch (179mg capsaicin cutaneous patch): effects on pain, quality of life, and patient satisfaction in painful diabetic peripheral neuropathy: an open-label, randomized controlled clinical trial. J Curr Med Res Opin. 2019;2(12):388–401. doi:10.15520/jcmro.v2i12.242
   Google Scholar
• Freynhagen R, Argoff C, Eerdekens M, Engelen S, Perrot S. Progressive response to repeat application of capsaicin 179 mg (8% w/w) cutaneous patch in peripheral neuropathic pain: comprehensive new analysis and clinical implications. Pain Med. 2021;22(10):2324–2336. doi:10.1093/pm/pnab113
   PubMed Web of Science ®Google Scholar
• van Nooten F, Treur M, Pantiri K, Stoker M, Charokopou M. Capsaicin 8% patch versus oral neuropathic pain medications for the treatment of painful diabetic peripheral neuropathy: a systematic literature review and network meta-analysis. Clin Ther. 2017;39(4):787–803.e18. doi:10.1016/j.clinthera.2017.02.010
   PubMed Web of Science ®Google Scholar
• Schwartz S, Etropolski M, Shapiro DY, et al. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin. 2011;27(1):151–162. doi:10.1185/03007995.2010.537589
   PubMed Web of Science ®Google Scholar
• Vinik AI, Shapiro DY, Rauschkolb C, et al. A randomized withdrawal, placebo-controlled study evaluating the efficacy and tolerability of tapentadol extended release in patients with chronic painful diabetic peripheral neuropathy. Diabetes Care. 2014;37(8):2302–2309. doi:10.2337/dc13-2291
   PubMed Web of Science ®Google Scholar
• Schwartz S, Etropolski MS, Shapiro DY, et al. A pooled analysis evaluating the efficacy and tolerability of tapentadol extended release for chronic, painful diabetic peripheral neuropathy. Clin Drug Investig. 2015;35(2):95–108. doi:10.1007/s40261-014-0249-3
   PubMed Web of Science ®Google Scholar
• Wang S-Y, Calderon J, Kuo Wang G. Block of neuronal Na+ channels by antidepressant duloxetine in a state-dependent manner. Anesthesiology. 2010;113(3):655–665. doi:10.1097/ALN.0b013e3181e89a93
   PubMed Web of Science ®Google Scholar
• Obata H. Analgesic mechanisms of antidepressants for neuropathic pain. Int J Mol Sci. 2017;18(11):2483. doi:10.3390/ijms18112483
   PubMed Web of Science ®Google Scholar
• Goldstein DJ, Lu Y, Detke MJ, Lee TC, Iyengar S. Duloxetine vs. placebo in patients with painful diabetic neuropathy. Pain. 2005;116(1–2):109–118. doi:10.1016/j.pain.2005.03.029
   PubMed Web of Science ®Google Scholar
• Wernicke JF, Pritchett YL, D’Souza DN, et al. A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology. 2006;67(8):1411–1420. doi:10.1212/01.wnl.0000240225.04000.1a
   PubMed Web of Science ®Google Scholar
• Chincholkar M. Gabapentinoids: pharmacokinetics, pharmacodynamics and considerations for clinical practice. Br J Pain. 2020;14(2):104–114. doi:10.1177/2049463720912496
   PubMed Web of Science ®Google Scholar
• Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology. 2004;63(11):2104–2110. doi:10.1212/01.Wnl.0000145767.36287.A1
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain. 2004;110(3):628–638. doi:10.1016/j.pain.2004.05.001
   PubMed Web of Science ®Google Scholar
• Parsons B, Li C. The efficacy of pregabalin in patients with moderate and severe pain due to diabetic peripheral neuropathy. Curr Med Res Opin. 2016;32(5):929–937. doi:10.1185/03007995.2016.1151776
   PubMed Web of Science ®Google Scholar
• Evoy KE, Sadrameli S, Contreras J, Covvey JR, Peckham AM, Morrison MD. Abuse and misuse of pregabalin and gabapentin: a systematic review update. Drugs. 2021;81(1):125–156. doi:10.1007/s40265-020-01432-7
   PubMed Web of Science ®Google Scholar
• Fornasari D. Pharmacotherapy for neuropathic pain: a review. Pain Ther. 2017;6(Suppl 1):25–33. doi:10.1007/s40122-017-0091-4
   PubMed Web of Science ®Google Scholar
• Coluzzi F, Mattia C. Mechanism-based treatment in chronic neuropathic pain: the role of antidepressants. Curr Pharm Des. 2005;11(23):2945–2960. doi:10.2174/1381612054864993
   PubMed Web of Science ®Google Scholar
• Max MB, Culnane M, Schafer SC, et al. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology. 1987;37(4):589–596. doi:10.1212/wnl.37.4.589
   PubMed Web of Science ®Google Scholar
• Boyle J, Eriksson MEV, Gribble L, et al. Randomized, placebo-controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning, and quality of life. Diabetes Care. 2012;35(12):2451–2458. doi:10.2337/dc12-0656
   PubMed Web of Science ®Google Scholar
• Shabbir B, Shafi F, Mahboob F. Amitriptyline vs pregabalin in painful diabetic neuropathy; a randomised placebo-based study. P J M H S. 2011;5(4):745–747.
   Google Scholar
• Moore RA, Derry S, Aldington D, Cole P, Wiffen PJ. Amitriptyline for neuropathic pain in adults. Cochrane Database Syst Rev. 2015;2015(7):Cd008242. doi:10.1002/14651858.CD008242.pub3
   PubMedGoogle Scholar
• Rudroju N, Bansal D, Talakokkula ST, et al. Comparative efficacy and safety of six antidepressants and anticonvulsants in painful diabetic neuropathy: a network meta-analysis. Pain Physician. 2013;16(6):E705–E714.
   PubMed Web of Science ®Google Scholar
• Asrar MM, Kumari S, Sekhar BC, Bhansali A, Bansal D. Relative efficacy and safety of pharmacotherapeutic interventions for diabetic peripheral neuropathy: a systematic review and Bayesian network meta-analysis. Pain Physician. 2021;24(1):E1–E14.
   PubMed Web of Science ®Google Scholar
• Derry S, Wiffen PJ, Aldington D, Moore RA. Nortriptyline for neuropathic pain in adults. Cochrane Database Syst Rev. 2015;1(1):Cd011209. doi:10.1002/14651858.CD011209.pub2
   PubMedGoogle Scholar
• Hearn L, Moore RA, Derry S, Wiffen PJ, Phillips T. Desipramine for neuropathic pain in adults. Cochrane Database Syst Rev. 2014;2014(9):Cd011003. doi:10.1002/14651858.CD011003.pub2
   PubMedGoogle Scholar
• Hearn L, Derry S, Phillips T, Moore RA, Wiffen PJ. Imipramine for neuropathic pain in adults. Cochrane Database Syst Rev. 2014;2014(5):Cd010769. doi:10.1002/14651858.CD010769.pub2
   PubMedGoogle Scholar
• Allen R, Sharma U, Barlas S. Clinical experience with desvenlafaxine in treatment of pain associated with diabetic peripheral neuropathy. J Pain Res. 2014;7:339–351. doi:10.2147/jpr.S55682
   PubMed Web of Science ®Google Scholar
• Rowbotham MC, Goli V, Kunz NR, Lei D. Venlafaxine extended release in the treatment of painful diabetic neuropathy: a double-blind, placebo-controlled study. Pain. 2004;110(3):697–706. doi:10.1016/j.pain.2004.05.010
   PubMed Web of Science ®Google Scholar
• Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA. 1998;280(21):1831–1836. doi:10.1001/jama.280.21.1831
   PubMed Web of Science ®Google Scholar
• Gorson KC, Schott C, Herman R, Ropper AH, Rand WM. Gabapentin in the treatment of painful diabetic neuropathy: a placebo controlled, double blind, crossover trial. J Neurol Neurosurg Psychiatry. 1999;66(2):251–252. doi:10.1136/jnnp.66.2.251
   PubMed Web of Science ®Google Scholar
• Meldrum BS, Rogawski MA. Molecular targets for antiepileptic drug development. Neurotherapeutics. 2007;4(1):18–61. doi:10.1016/j.nurt.2006.11.010
   PubMed Web of Science ®Google Scholar
• Zuliani V, Rivara M, Fantini M, Costantino G. Sodium channel blockers for neuropathic pain. Expert Opin Ther Pat. 2010;20(6):755–779. doi:10.1517/13543771003774118
   PubMed Web of Science ®Google Scholar
• Shaibani A, Fares S, Selam JL, et al. Lacosamide in painful diabetic neuropathy: an 18-week double-blind placebo-controlled trial. J Pain. 2009;10(8):818–828. doi:10.1016/j.jpain.2009.01.322
   PubMed Web of Science ®Google Scholar
• Wymer JP, Simpson J, Sen D, Bongardt S. Efficacy and safety of lacosamide in diabetic neuropathic pain: an 18-week double-blind placebo-controlled trial of fixed-dose regimens. Clin J Pain. 2009;25(5):376–385. doi:10.1097/AJP.0b013e318196d2b6
   PubMed Web of Science ®Google Scholar
• Eisenberg E, Lurie Y, Braker C, Daoud D, Ishay A. Lamotrigine reduces painful diabetic neuropathy: a randomized, controlled study. Neurology. 2001;57(3):505–509. doi:10.1212/wnl.57.3.505
   PubMed Web of Science ®Google Scholar
• Vinik AI, Tuchman M, Safirstein B, et al. Lamotrigine for treatment of pain associated with diabetic neuropathy: results of two randomized, double-blind, placebo-controlled studies. Pain. 2007;128(1):169–179. doi:10.1016/j.pain.2006.09.040
   PubMed Web of Science ®Google Scholar
• Dogra S, Beydoun S, Mazzola J, Hopwood M, Wan Y. Oxcarbazepine in painful diabetic neuropathy: a randomized, placebo-controlled study. Eur J Pain. 2005;9(5):543–554. doi:10.1016/j.ejpain.2004.11.006
   PubMed Web of Science ®Google Scholar
• Grosskopf J, Mazzola J, Wan Y, Hopwood M. A randomized, placebo-controlled study of oxcarbazepine in painful diabetic neuropathy. Acta Neurol Scand. 2006;114(3):177–180. doi:10.1111/j.1600-0404.2005.00559.x
   PubMed Web of Science ®Google Scholar
• Kochar DK, Jain N, Agarwal RP, Srivastava T, Agarwal P, Gupta S. Sodium valproate in the management of painful neuropathy in type 2 diabetes - A randomized placebo controlled study. Acta Neurol Scand. 2002;106(5):248–252. doi:10.1034/j.1600-0404.2002.01229.x
   PubMed Web of Science ®Google Scholar
• Kochar DK, Rawat N, Agrawal RP, et al. Sodium valproate for painful diabetic neuropathy: a randomized double-blind placebo-controlled study. Qjm. 2004;97(1):33–38. doi:10.1093/qjmed/hch007
   PubMed Web of Science ®Google Scholar
• Sansone RA, Sansone LA. Serotonin norepinephrine reuptake inhibitors: a pharmacological comparison. Innov Clin Neurosci. 2014;11(3–4):1.
   Google Scholar
• Neurontin® (Gabapentin) Capsules, Tablets, Solution, for Oral Use: US Prescribing Information. New York, NY: Pfizer Inc; 2020.
   Google Scholar
• Theile JW, Cummins TR. Recent developments regarding voltage-gated sodium channel blockers for the treatment of inherited and acquired neuropathic pain syndromes. Front Pharmacol. 2011;2:54. doi:10.3389/fphar.2011.00054
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. U.S. National Library of Medicine. Available from https://clinicaltrials.gov. Accessed June 9, 2022.
   Google Scholar
• Kessler JA, Shaibani A, Sang CN, et al. Gene therapy for diabetic peripheral neuropathy: a randomized, placebo-controlled Phase III study of VM202, a plasmid DNA encoding human hepatocyte growth factor. Clin Transl Sci. 2021;14(3):1176–1184. doi:10.1111/cts.12977
   PubMed Web of Science ®Google Scholar
• Tiecke E, Rainisio M, Eisenberg E, et al. NRD.E1, an innovative non-opioid therapy for painful diabetic peripheral neuropathy-A randomized proof of concept study. Eur J Pain. 2022;26(8):1665–1678. doi:10.1002/ejp.1989
   PubMed Web of Science ®Google Scholar
• Anand U, Yiangou Y, Sinisi M, et al. Mechanisms underlying clinical efficacy of Angiotensin II type 2 receptor (AT2R) antagonist EMA401 in neuropathic pain: clinical tissue and in vitro studies. Mol Pain. 2015;11:38. doi:10.1186/s12990-015-0038-x
   PubMed Web of Science ®Google Scholar
• Rice ASC, Dworkin RH, Finnerup NB, et al. Efficacy and safety of EMA401 in peripheral neuropathic pain: results of 2 randomised, double-blind, phase 2 studies in patients with postherpetic neuralgia and painful diabetic neuropathy. Pain. 2021;162(10):2578–2589. doi:10.1097/j.pain.0000000000002252
   PubMed Web of Science ®Google Scholar
• Chalk C, Benstead TJ, Moore F. Aldose reductase inhibitors for the treatment of diabetic polyneuropathy. Cochrane Database Syst Rev. 2007;2007(4):Cd004572. doi:10.1002/14651858.CD004572.pub2
   PubMedGoogle Scholar
• Talbot S, Couture R. Emerging role of microglial kinin B1 receptor in diabetic pain neuropathy. Exp Neurol. 2012;234(2):373–381. doi:10.1016/j.expneurol.2011.11.032
   PubMed Web of Science ®Google Scholar
• Rahn EJ, Hohmann AG. Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside. Neurotherapeutics. 2009;6(4):713–737. doi:10.1016/j.nurt.2009.08.002
   PubMed Web of Science ®Google Scholar
• Zebala JA, Searle SL, Webster LR, et al. Desmetramadol has the safety and analgesic profile of tramadol without its metabolic liabilities: consecutive randomized, double-blind, placebo- and active comparator-controlled trials. J Pain. 2019;20(10):1218–1235. doi:10.1016/j.jpain.2019.04.005
   PubMed Web of Science ®Google Scholar
• Weyer AD, Lehto SG. Development of TRPM8 antagonists to treat chronic pain and migraine. Pharmaceuticals (Basel). 2017;10(2):37. doi:10.3390/ph10020037
   PubMedGoogle Scholar
• Kostich W, Hamman BD, Li YW, et al. Inhibition of AAK1 kinase as a novel therapeutic approach to treat neuropathic pain. J Pharmacol Exp Ther. 2016;358(3):371–386. doi:10.1124/jpet.116.235333
   PubMed Web of Science ®Google Scholar
• Julius D. TRP channels and pain. Annu Rev Cell Dev Biol. 2013;29:355–384. doi:10.1146/annurev-cellbio-101011-155833
   PubMed Web of Science ®Google Scholar
• Verma V, Khoury S, Parisien M, et al. The dichotomous role of epiregulin in pain. Pain. 2020;161(5):1052–1064. doi:10.1097/j.pain.0000000000001792
   PubMed Web of Science ®Google Scholar
• Uchida K, Takano S, Matsumoto T, et al. Transforming growth factor activating kinase 1 regulates extracellular matrix degrading enzymes and pain-related molecule expression following tumor necrosis factor-α stimulation of synovial cells: an in vitro study. BMC Musculoskelet Disord. 2017;18(1):283. doi:10.1186/s12891-017-1648-4
   PubMedGoogle Scholar
• Mizumura K, Murase S. Role of nerve growth factor in pain. Handb Exp Pharmacol. 2015;227:57–77. doi:10.1007/978-3-662-46450-2_4
   PubMedGoogle Scholar
• Li J, Yu M, Fu S, Liu D, Tan Y. Role of selective histone deacetylase 6 inhibitor ACY-1215 in cancer and other human diseases. Front Pharmacol. 2022;13:907981. doi:10.3389/fphar.2022.907981
   PubMed Web of Science ®Google Scholar
• Rupp A, Young E, Chadwick AL. Low-dose naltrexone’s utility for non-cancer centralized pain conditions: a scoping review. Pain Med. 2023;24(11):1270–1281. doi:10.1093/pm/pnad074
   PubMed Web of Science ®Google Scholar
• Srinivasan A, Dutta P, Bansal D, et al. Efficacy and safety of low-dose naltrexone in painful diabetic neuropathy: a randomized, double-blind, active-control, crossover clinical trial. J Diabetes. 2021;13(10):770–778. doi:10.1111/1753-0407.13202
   PubMed Web of Science ®Google Scholar
• Stein C, Eibel B, Sbruzzi G, Lago PD, Plentz RD. Electrical stimulation and electromagnetic field use in patients with diabetic neuropathy: systematic review and meta-analysis. Braz J Phys Ther. 2013;17(2):93–104. doi:10.1590/s1413-35552012005000083
   PubMed Web of Science ®Google Scholar
• Bosi E, Bax G, Scionti L, et al. Frequency-modulated electromagnetic neural stimulation (FREMS) as a treatment for symptomatic diabetic neuropathy: results from a double-blind, randomised, multicentre, long-term, placebo-controlled clinical trial. Diabetologia. 2013;56(3):467–475. doi:10.1007/s00125-012-2795-7
   PubMed Web of Science ®Google Scholar
• Bosi E, Conti M, Vermigli C, et al. Effectiveness of frequency-modulated electromagnetic neural stimulation in the treatment of painful diabetic neuropathy. Diabetologia. 2005;48(5):817–823. doi:10.1007/s00125-005-1734-2
   PubMed Web of Science ®Google Scholar
• Lavery LA, Murdoch DP, Williams J, Lavery DC. Does anodyne light therapy improve peripheral neuropathy in diabetes? A double-blind, sham-controlled, randomized trial to evaluate monochromatic infrared photoenergy. Diabetes Care. 2008;31(2):316–321. doi:10.2337/dc07-1794
   PubMed Web of Science ®Google Scholar
• Thakral G, Kim PJ, LaFontaine J, Menzies R, Najafi B, Lavery LA. Electrical stimulation as an adjunctive treatment of painful and sensory diabetic neuropathy. J Diabetes Sci Technol. 2013;7(5):1202–1209. doi:10.1177/193229681300700510
   PubMedGoogle Scholar
• Papanas N, Ziegler D. Emerging drugs for diabetic peripheral neuropathy and neuropathic pain. Expert Opin Emerg Drugs. 2016;21(4):393–407. doi:10.1080/14728214.2016.1257605
   PubMed Web of Science ®Google Scholar
• Narayanaswamy H, Facer P, Misra VP, et al. A longitudinal study of sensory biomarkers of progression in patients with diabetic peripheral neuropathy using skin biopsies. J Clin Neurosci. 2012;19(11):1490–1496. doi:10.1016/j.jocn.2011.12.026
   PubMed Web of Science ®Google Scholar
• Ziegler D, Papanas N, Schnell O, et al. Current concepts in the management of diabetic polyneuropathy. J Diabetes Investig. 2021;12(4):464–475. doi:10.1111/jdi.13401
   PubMed Web of Science ®Google Scholar
• Khan H, Singh TG, Dahiya RS, Abdel-Daim MM. α-Lipoic acid, an organosulfur biomolecule a novel therapeutic agent for neurodegenerative disorders: an mechanistic perspective. Neurochem Res. 2022;47(7):1853–1864. doi:10.1007/s11064-022-03598-w
   PubMed Web of Science ®Google Scholar
• Papanas N, Ziegler D. Efficacy of α-lipoic acid in diabetic neuropathy. Expert Opin Pharmacother. 2014;15(18):2721–2731. doi:10.1517/14656566.2014.972935
   PubMed Web of Science ®Google Scholar
• Pai ST. Chapter 13 - Peripheral Neuropathy. In: Rakel D, editor. Integrative Medicine. Fourth Edition) ed. Elsevier; 2018:120–132.e8.
   Google Scholar
• Stracke H, Gaus W, Achenbach U, Federlin K, Bretzel RG. Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study. Exp Clin Endocrinol Diabetes. 2008;116(10):600–605. doi:10.1055/s-2008-1065351
   PubMed Web of Science ®Google Scholar
• Shevalye H, Watcho P, Stavniichuk R, Dyukova E, Lupachyk S, Obrosova IG. Metanx alleviates multiple manifestations of peripheral neuropathy and increases intraepidermal nerve fiber density in Zucker diabetic fatty rats. Diabetes. 2012;61(8):2126–2133. doi:10.2337/db11-1524
   PubMed Web of Science ®Google Scholar
• Fonseca VA, Lavery LA, Thethi TK, et al. Metanx in type 2 diabetes with peripheral neuropathy: a randomized trial. Am J Med. 2013;126(2):141–149. doi:10.1016/j.amjmed.2012.06.022
   PubMed Web of Science ®Google Scholar
• Hor CP, Fung WY, Ang HA, et al. Efficacy of oral mixed tocotrienols in diabetic peripheral neuropathy: a randomized clinical trial. JAMA Neurol. 2018;75(4):444–452. doi:10.1001/jamaneurol.2017.4609
   PubMed Web of Science ®Google Scholar
• Ziegler D, Porta M, Papanas N, et al. The role of biofactors in diabetic microvascular complications. Curr Diabetes Rev. 2022;18(4):e250821195830. doi:10.2174/1871527320666210825112240
   PubMed Web of Science ®Google Scholar
• Sadosky A, Mardekian J, Parsons B, Hopps M, Bienen EJ, Markman J. Healthcare utilization and costs in diabetes relative to the clinical spectrum of painful diabetic peripheral neuropathy. J Diabetes Complications. 2015;29(2):212–217. doi:10.1016/j.jdiacomp.2014.10.013
   PubMed Web of Science ®Google Scholar
• Bastyr EJ 3rd, Price KL, Bril V. Development and validity testing of the neuropathy total symptom score-6: questionnaire for the study of sensory symptoms of diabetic peripheral neuropathy. Clin Ther. 2005;27(8):1278–1294. doi:10.1016/j.clinthera.2005.08.002
   PubMed Web of Science ®Google Scholar
• Bril V, Tomioka S, Buchanan RA, Perkins BA. Reliability and validity of the modified Toronto Clinical Neuropathy Score in diabetic sensorimotor polyneuropathy. Diabet Med. 2009;26(3):240–246. doi:10.1111/j.1464-5491.2009.02667.x
   PubMed Web of Science ®Google Scholar
• Saydah SH. Medication use and self-care practices in persons with diabetes. In: Cowie CC, Casagrande SS, Menke A, editors. Diabetes in America. 3rd ed. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases (US); 2018:chapter 39.
   Google Scholar
• Gore M, Brandenburg NA, Hoffman DL, Tai K-S, Stacey B. Burden of illness in painful diabetic peripheral neuropathy: the patients’ perspectives. J Pain. 2006;7(12):892–900. doi:10.1016/j.jpain.2006.04.013
   PubMed Web of Science ®Google Scholar
• Stillman M. Clinical approach to patients with neuropathic pain. Cleve Clin J Med. 2006;73(8):726–736 passim. doi:10.3949/ccjm.73.8.726
   PubMed Web of Science ®Google Scholar
• Deer TR, Pope JE, Hanes MC, McDowell GC. Intrathecal therapy for chronic pain: a review of morphine and ziconotide as firstline options. Pain Med. 2019;20(4):784–798. doi:10.1093/pm/pny132
   PubMed Web of Science ®Google Scholar
• Deer TR, Hayek SM, Pope JE, et al. The Polyanalgesic Consensus Conference (PACC): recommendations for trialing of intrathecal drug delivery infusion therapy. Neuromodulation. 2017;20(2):133–154. doi:10.1111/ner.12543
   PubMed Web of Science ®Google Scholar